Word

VACSAF

Status

Registered

Status Code

700

Status Date

Tuesday, January 15, 2019

Serial Number

79221183

Registration Number

5651894

Registration Date

Tuesday, January 15, 2019

Mark Type

4000

Filing Date

Friday, October 27, 2017

Published for Opposition

Tuesday, October 30, 2018

Trademark Owner History

SISAF Ltd - Original Registrant

Classifications

5 Antiviral pharmaceutical preparations, anti-infective pharmaceutical preparations, anti-inflammatory pharmaceutical preparations, antiseptic pharmaceutical preparations, antibacterial pharmaceutical preparations, antibiotic pharmaceutical preparations, antifungal pharmaceutical preparations, and anti-fibrotic pharmaceutical preparations; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment and prevention of cardiovascular diseases and disorders, musculoskeletal diseases and disorders, inflammatory diseases and disorders, respiratory diseases and disorders, pulmonary diseases and disorders, immune system related diseases and disorders, hematological diseases and disorders, oncological diseases and disorders, urological diseases and disorders, gastro-intestinal diseases, eye diseases and conditions, heart rhythm disorders, kidney diseases, nephropathic diseases, hematological disorders, diabetes, hypertension, skin disorders, damaged skin and tissue, wrinkles, wounds and allergies, insect bites, dermatological diseases and disorders, HIV, cancer and tumors, bone diseases, arthritis, cardiopulmonary diseases and disorders, infectious diseases, blood disorders, pain, sepsis, alopecia, obesity, cognitive disorders and diseases, neurological disorders, hormonal disorders, disorders of the autoimmune system, metabolic system diseases and disorders, endocrine system diseases and disorders, genitourinary system diseases and disorders; Preparations in the nature of animal feed supplements containing trace elements; Preparations in the nature of human vaccine preparations containing trace elements; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals, nutraceutical and veterinary products; Drug delivery agents consisting of nanoparticle compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; Drug delivery agents consisting of silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; Drug delivery agents consisting of porous silicon compounds that facilitate delivery of a wide range of pharmaceutical, nutraceutical and veterinary products; drug delivery agents consisting of compounds for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical vaccines; Drug delivery agents consisting of compounds for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; drug delivery agents consisting of compounds containing silicon-based porous nanoparticles for facilitating the delivery of chemical, biochemical, biological, and pharmaceutical antibiotics; Chemical, biochemical, biological and pharmaceutical substances for medicinal use being pharmaceutical preparation stabilizers

1 Chemicals and chemical preparations for use in industry, science and research; Biochemical substances and biochemical preparations for use in industry, science and research, namely, excipients for use in the manufacture of pharmaceutical preparations, cosmetic preparations, nutraceutical preparations, veterinary preparations, dietary supplements, foods and pharmaceutical preparations for topical use; Chemical preparations for pharmaceutical, medical and veterinary research in the nature of reagents and substrates, namely, chemical compounds for use in patterning at nano scale or near nano scale; Silicon for use in industry, science and research; Silicon nanoparticle materials, namely, silicon and silicon-based chemical compounds for use in industry, science and research; Porous silicon nanoparticle materials, namely, silicon and silicon-based chemical compounds for use in industry, science and research; Chemical materials, namely, chemical catalysts for carrying and delivery of chemical, biochemical and biological substances for use in industry and not for medical or veterinary use; Silicon for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Nanoparticle materials, namely, silicon-based chemical compounds for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Silicon nanoparticle materials being silicon-based chemical compounds for use in stabilising enzymes of chemical, biochemical and biological substances for scientific research purposes; Porous silicon nanoparticle materials being silicon-based chemical compounds for stabilising enzymes of chemical, biochemical and biological substances for use in industry and for scientific research purposes; Chemicals and chemical preparations, namely, reagents and catalysts for pharmaceutical research purposes; Chemicals and chemical preparations, namely, reagents and catalysts for scientific research in the field of medicine, veterinary and pharmaceutics; Excipient for use in the manufacture of pharmaceutical products, including for the manufacture of vaccines and veterinary preparations

VAC SAF; VACCINE SAFE

Trademark Events

Jan 15, 2024

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

May 17, 2019

Final Decision Transaction Processed By Ib

May 1, 2019

Final Disposition Notice Sent To Ib

Apr 30, 2019

Final Disposition Processed

Apr 15, 2019

Final Disposition Notice Created, To Be Sent To Ib

Jan 15, 2019

Registered-Principal Register

Dec 14, 2018

Teas Change Of Correspondence Received

Oct 30, 2018

Official Gazette Publication Confirmation E-Mailed

Oct 30, 2018

Published For Opposition

Oct 26, 2018

Notification Processed By Ib

Oct 10, 2018

Notification Of Possible Opposition Sent To Ib

Oct 10, 2018

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Oct 10, 2018

Notification Of Notice Of Publication E-Mailed

Sep 18, 2018

Approved For Pub - Principal Register

Sep 18, 2018

Examiner's Amendment Entered

Sep 18, 2018

Notification Of Examiners Amendment E-Mailed

Sep 18, 2018

Examiners Amendment E-Mailed

Sep 18, 2018

Examiners Amendment -Written

Aug 31, 2018

Teas/Email Correspondence Entered

Aug 31, 2018

Correspondence Received In Law Office

Aug 30, 2018

Assigned To Lie

Aug 15, 2018

Teas Response To Office Action Received

Mar 9, 2018

Refusal Processed By Ib

Feb 16, 2018

Non-Final Action Mailed - Refusal Sent To Ib

Feb 16, 2018

Refusal Processed By Mpu

Feb 13, 2018

Non-Final Action (Ib Refusal) Prepared For Review

Feb 12, 2018

Non-Final Action Written

Feb 6, 2018

Assigned To Examiner

Nov 29, 2017

Application Filing Receipt Mailed

Nov 25, 2017

New Application Office Supplied Data Entered

Nov 16, 2017

Sn Assigned For Sect 66a Subseq Desig From Ib